| Dr Peter Mark Fernandez, MD | |
|
3920 Bee Ridge Rd Ste Ca, Sarasota, FL 34233-1260 | |
| (941) 867-7463 | |
| (941) 870-3839 |
| Full Name | Dr Peter Mark Fernandez |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 21 Years |
| Location | 3920 Bee Ridge Rd Ste Ca, Sarasota, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457560294 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | ME104715 (Florida) | Primary |
| 207LP2900X | Anesthesiology - Pain Medicine | ME104715 (Florida) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lopez Pain Management Llc | 8325323538 | 3 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | Spartan Anesthesia Associates P.a |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710975636 PECOS PAC ID: 0446158745 Enrollment ID: O20031223000637 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | Anesthesiology Professional Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902856891 PECOS PAC ID: 4688577141 Enrollment ID: O20040130000927 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | John D. Woody, Md, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063465524 PECOS PAC ID: 4789613076 Enrollment ID: O20050808000181 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | Sarasota Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689857393 PECOS PAC ID: 4284708207 Enrollment ID: O20080808000213 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | Orange City Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972882314 PECOS PAC ID: 2365617016 Enrollment ID: O20111208000641 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | Restore Medical Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891148250 PECOS PAC ID: 1951682426 Enrollment ID: O20161227000510 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Entity Name | Lopez Pain Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871032466 PECOS PAC ID: 8325323538 Enrollment ID: O20170329002453 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Mark Fernandez, MD 3920 Bee Ridge Rd Bldg C, Sarasota, FL 34233-1207 Ph: (941) 867-7463 | Dr Peter Mark Fernandez, MD 3920 Bee Ridge Rd Ste Ca, Sarasota, FL 34233-1260 Ph: (941) 867-7463 |
News Archive
A surgical technique that requires the removal, restructure and re-implantation of the nasal septum (the partition of the nose between the nostrils) appears to be a useful option for repairing the hard-to-treat severely deviated septum, according to an article in the July/August issue of Archives of Facial Plastic Surgery.
Lancaster Online: "Most Americans who have health insurance are pleased with their coverage, a new national Franklin & Marshall College poll shows. But many of those same people are worried about those who can't afford insurance, and overwhelmingly believe the health care system needs to be reformed, according to a survey of 920 adults. ... The survey found that 75 percent of Americans who have insurance rate their coverage as good or very good — the same percentage who believe the health-care system is in need of reform.
A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.
"By the 4th week post-transplantation the patient enjoyed his first dinner in 9 years (bread and sausages); before reconstruction he had only been able to eat soft food and soup".
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 6 days ago
Lynn R Fassy, M.D. Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 3945 Clark Rd, Sarasota, FL 34233 Phone: 941-926-4770 Fax: 941-923-2520 | |
Donald Louis Erb, D.O. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 6050 Cattleridge Blvd Ste 201, Sarasota, FL 34232 Phone: 941-365-0655 Fax: 941-366-8043 | |
Michael B. Auerbach, D.O. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 5741 Bee Ridge Rd, Suite 210, Sarasota, FL 34233 Phone: 941-365-5672 | |
Dr. Justin Michael Raye, D.O. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2750 Bahia Vista St Ste 100, Sarasota, FL 34239 Phone: 941-951-2663 Fax: 941-552-3312 | |
Dr. Judith Anne Pollett, M.D. Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 5955 Rand Blvd, Sarasota, FL 34238 Phone: 941-552-7530 Fax: 941-552-4883 | |
Eugene G Pereira, MD Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2030 Bee Ridge Rd Ste B, Sarasota, FL 34239 Phone: 941-845-0233 Fax: 941-538-6063 |